Alk
Alk, officially known as Alk Abello A/S, is a leading player in the biopharmaceutical industry, headquartered in Denmark (DK). Founded in 1923, the company has established itself as a pioneer in allergy immunotherapy, focusing on innovative treatments for allergic conditions. With a strong presence in Europe and North America, Alk is dedicated to improving the quality of life for allergy sufferers through its advanced products. The company’s core offerings include sublingual and injectable immunotherapy solutions, which are distinguished by their efficacy and patient-friendly administration methods. Alk's commitment to research and development has positioned it as a market leader, achieving significant milestones such as the introduction of the first sublingual tablet for grass pollen allergy. With a robust portfolio and a focus on patient-centric solutions, Alk continues to drive advancements in allergy treatment.
DitchCarbon Score
How does Alk's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Alk's score of 49 is higher than 98% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Alk's reported carbon emissions
In 2023, ALK-Abelló A/S reported total carbon emissions of approximately 69,776,000 kg CO2e, comprising 3,207,000 kg CO2e from Scope 1, 6,104,000 kg CO2e from Scope 2, and a significant 64,067,000 kg CO2e from Scope 3 emissions. This marked a notable increase from 2022, where total emissions were about 75,967,000 kg CO2e. The company has set ambitious climate commitments, aiming to reduce its absolute Scope 1 and 2 greenhouse gas emissions by 42% by 2030, using 2022 as the baseline year. Additionally, ALK-Abelló has pledged that by 2028, 80% of its suppliers, based on emissions from purchased goods and services, capital goods, and transportation, will have established science-based targets. These targets align with the 1.5°C pathway, demonstrating ALK-Abelló's commitment to addressing climate change and reducing its carbon footprint in the pharmaceutical and biotechnology sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Scope 1 | 5,479,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 6,511,000 | 0,000,000 | 0,000,000 | 000,000 | 000,000 | 000,000 |
| Scope 3 | - | - | - | 00,000,000 | 00,000,000 | 00,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Alk is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
